Search Results

In the latest example of big pharma entering AI collaborations or using AI-based tools, AstraZeneca’s deal with Absci will aim to produce an oncology candidate.

Almirall S.A. and Absci Corporation announced a drug discovery partnership aimed to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases.

Absci Corporation inked a deal with Merck. Absci will leverage its Bionic Protein non-standard amino acid technology and AI-integrated Drug Creation Platform to create enzymes for Merck.

CerraCap Ventures, a leading early-stage Venture Fund, announced acquisition of its portfolio company Totient by Absci for an undisclosed amount.

AbSci today announced the acquisition of Totient, a discovery company harnessing human immune responses to identify novel antibodies and their therapeutic targets.

Viva Biotech declared that Totient, one of its portfolio companies, has been acquired by AbSci, a synthetic biology company unlocking the potential of proteins as next-generation therapeutics.

EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and Absci Corporation, the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, announced a discovery collaboration.

Absci, the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, announced two strategic hires joining its executive team: Nikhil Goel as Chief Business Officer and Dr. Sarah Korman as General Counsel.

Integration of Denovium Engine™ with AbSci’s Protein Printing™ Platform to enable creation of novel biotherapeutics and manufacturing cell lines with the click of a button

AbSci, a growth-stage synthetic biology company whose Protein Printing™ technology enables rapid and low-cost biomanufacturing and discovery of biotherapeutics, today announced that Ivana Magovčević-Lie